Article citationsMore>>

Smith, C.C., Levis, M.J., Perl, A.E., Hill, J.E., Rosales, M. and Bahceci, E. (2022) Molecular Profile of FLT3-Mutated Relapsed/refractory Patients with AML in the Phase 3 ADMIRAL Study of Gilteritinib. Blood Advances, 6, 2144-2155.
https://doi.org/10.1182/bloodadvances.2021006489

has been cited by the following article:

• TITLE: A Primary Breast Hodgkin Lymphoma: A Case Report

  AUTHORS: Khadija Essrifi, Hicham Eddou

  KEYWORDS: Hodgkin Lymphoma, Breast Lymphoma, Immunochemistry, Chemotherapy

  JOURNAL NAME: Case Reports in Clinical Medicine, Vol.14 No.8, August 19, 2025

  ABSTRACT: Primary breast Hodgkin lymphoma is an uncommon and rare type of breast malignancy with little clinical and imaging specificity. As in all forms of Hodgkin lymphoma (HL), the diagnosis of breast HL is difficult and can only be made if an immunohistochemical study is carried out to exclude other types of cancer and avoid unnecessary surgery. The role of positron emission tomography scanning (PET/CT) is important in assessing lesions and making treatment decisions. We present a unique case of primary breast Hodgkin lymphoma in a 49-year-old woman. The diagnosis is confirmed by histology. Immunohistochemistry on an axillary lymph node biopsy. A complete response was obtained after first-line chemotherapy: BEACOP-DAC (bleomycin-dacarbazine-cyclophosphamide-doxorubicin-etoposide-vincristine). Furthermore, the patient did not receive radiotherapy.